| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025737808 |
| P356 | DOI | 10.1208/AAPSJ080125 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1208/aapsj080125 |
| P932 | PMC publication ID | 2751441 |
| P698 | PubMed publication ID | 16584130 |
| P5875 | ResearchGate publication ID | 7196125 |
| P2093 | author name string | Nagaraju Akula | |
| Jayalakshmi Sridhar | |||
| Nagarajan Pattabiraman | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| The Sequence of the Human Genome | Q22065842 | ||
| CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice | Q24286950 | ||
| Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation | Q45152513 | ||
| Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin | Q45249707 | ||
| Homology model of the CDK1/cyclin B complex. | Q45259068 | ||
| Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases. | Q46394288 | ||
| Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors | Q46420261 | ||
| Synthesis and biological evaluation of 2-thiopyrimidine derivatives | Q46421170 | ||
| Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. | Q47406939 | ||
| Cdc2-cyclin B phosphorylates p70 S6 kinase on Ser411 at mitosis | Q48010488 | ||
| Inhibition of cyclin-dependent kinases by purine analogues. | Q49090586 | ||
| Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. | Q52076668 | ||
| Occluded molecular surface analysis of ligand-macromolecule contacts: application to HIV-1 protease-inhibitor complexes. | Q52143448 | ||
| Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons | Q71070114 | ||
| A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces | Q72741849 | ||
| Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc | Q77343404 | ||
| Abnormalities in cell cycle control in cancer and their clinical implications | Q77588178 | ||
| Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes | Q80801333 | ||
| Cyclin-dependent kinase 5 and neuronal migration in the neocortex | Q35606840 | ||
| Cdk5: a new player at synapses | Q35606844 | ||
| Role of Cdk5 in neuronal signaling, plasticity, and drug abuse | Q35606849 | ||
| Role of cdk5 in the pathogenesis of Alzheimer's disease | Q35606854 | ||
| Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis | Q35606858 | ||
| Protein kinase inhibitors: insights into drug design from structure. | Q35697409 | ||
| Chemical inhibitors of cyclin-dependent kinases | Q35780698 | ||
| Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions | Q36676197 | ||
| Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease | Q37089784 | ||
| Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues | Q39757012 | ||
| Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus | Q40427848 | ||
| Cyclins and cyclin-dependent kinases: theme and variations | Q40551569 | ||
| 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity | Q40577383 | ||
| A new series of potent oxindole inhibitors of CDK2. | Q40580263 | ||
| 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. | Q40615616 | ||
| Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest | Q40748304 | ||
| Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity | Q40939103 | ||
| The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts | Q40967344 | ||
| Defining the minimal portion of the retinoblastoma protein that serves as an efficient substrate for cdk4 kinase/cyclin D1 complex | Q41027112 | ||
| Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? | Q41066914 | ||
| The dynamics of cyclin dependent kinase structure | Q41239067 | ||
| Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage | Q41320093 | ||
| Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases | Q41628594 | ||
| The regulation and functions of cdk7. | Q41743937 | ||
| The crystal structure of human CDK7 and its protein recognition properties | Q42152402 | ||
| Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. | Q42524390 | ||
| Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties | Q42552785 | ||
| Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. | Q42555777 | ||
| Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. | Q43548171 | ||
| 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues | Q44489607 | ||
| Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors | Q44841683 | ||
| Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease | Q45105706 | ||
| Structure and regulation of the CDK5-p25(nck5a) complex | Q27635171 | ||
| Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis | Q27636502 | ||
| Structure-based design and protein X-ray analysis of a protein kinase inhibitor | Q27637078 | ||
| Structural basis for CDK6 activation by a virus-encoded cyclin | Q27637630 | ||
| Structural studies on phospho-CDK2/cyclin A bound to nitrate, a transition state analogue: implications for the protein kinase mechanism | Q27639070 | ||
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives | Q27639415 | ||
| Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity | Q27639756 | ||
| Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A | Q27640246 | ||
| Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop | Q27640893 | ||
| 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors | Q27641653 | ||
| Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines | Q27641908 | ||
| Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation | Q27641909 | ||
| SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2 | Q27642330 | ||
| Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition | Q27642494 | ||
| Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange | Q27642698 | ||
| The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines | Q27643052 | ||
| Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine | Q27729294 | ||
| Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex | Q27729793 | ||
| Three-dimensional structure of human cyclin H, a positive regulator of the CDK-activating kinase | Q27733461 | ||
| High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design | Q27733909 | ||
| Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine | Q27734755 | ||
| Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 | Q27746054 | ||
| Structure of the cyclin-dependent kinase inhibitor p19Ink4d | Q27746702 | ||
| Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations | Q27748800 | ||
| Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4 | Q27760543 | ||
| Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors | Q27764855 | ||
| Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d | Q27765359 | ||
| CDK inhibitors: positive and negative regulators of G1-phase progression | Q27860983 | ||
| CDC25 phosphatases as potential human oncogenes | Q28116546 | ||
| TFIIH is negatively regulated by cdk8-containing mediator complexes | Q28138931 | ||
| Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential | Q28263701 | ||
| Rb interacts with histone deacetylase to repress transcription | Q28263985 | ||
| Physical interaction of the retinoblastoma protein with human D cyclins | Q28269103 | ||
| Characterization of novel inhibitors of cyclin-dependent kinases | Q28369139 | ||
| Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2 | Q24291461 | ||
| Mechanism of CDK5/p25 binding by CDK inhibitors | Q24293582 | ||
| 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding | Q24296298 | ||
| N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2 | Q24298676 | ||
| Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor | Q24307480 | ||
| Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals | Q24314293 | ||
| Structural basis of cyclin-dependent kinase activation by phosphorylation | Q24315902 | ||
| Cyclin-binding motifs are essential for the function of p21CIP1 | Q24316125 | ||
| Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a | Q24316348 | ||
| Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2 | Q24318338 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex | Q24336704 | ||
| Cyclin C/cdk3 promotes Rb-dependent G0 exit | Q24336871 | ||
| Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors | Q24597269 | ||
| Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data | Q24672116 | ||
| Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A | Q27617472 | ||
| Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity | Q27617593 | ||
| Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6 | Q27618655 | ||
| Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C) | Q27620333 | ||
| The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases | Q27620372 | ||
| Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase | Q27620981 | ||
| Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent | Q27621242 | ||
| Crystal structure of a gamma-herpesvirus cyclin-cdk complex | Q27624932 | ||
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles | Q27626674 | ||
| Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors | Q27629159 | ||
| Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717 | Q27629421 | ||
| Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein | Q27631578 | ||
| Quinazolines as cyclin dependent kinase inhibitors | Q27631791 | ||
| Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate | Q27632159 | ||
| Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases | Q28377579 | ||
| p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment | Q28589437 | ||
| The Inhibitor of Cyclin-Dependent Kinase 4a/Alternative Reading Frame (INK4a/ARF) Locus Encoded Proteins p16INK4a and p19ARF Repress Cyclin D1 Transcription through Distinct cis Elements | Q29036277 | ||
| Principles of CDK regulation | Q29547820 | ||
| Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases | Q29614338 | ||
| Cyclin-dependent kinases: engines, clocks, and microprocessors | Q29614786 | ||
| Protein kinases--the major drug targets of the twenty-first century? | Q29615339 | ||
| CLUSTAL V: improved software for multiple sequence alignment | Q29617279 | ||
| Crystal structure of cyclin-dependent kinase 2 | Q29622946 | ||
| Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design | Q30777277 | ||
| Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. | Q31526877 | ||
| Parallel synthesis of acylsemicarbazide libraries: preparation of potent cyclin dependent kinase (cdk) inhibitors | Q33207893 | ||
| Repression of TFIIH transcriptional activity and TFIIH-associated cdk7 kinase activity at mitosis | Q33772499 | ||
| Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. | Q33889556 | ||
| The role of the Cdk5--p35 kinase in neuronal development | Q33937967 | ||
| Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity | Q33943441 | ||
| The Pezcoller lecture: cancer cell cycles revisited | Q33987290 | ||
| The Rb/E2F pathway: expanding roles and emerging paradigms | Q34052659 | ||
| Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle | Q34076834 | ||
| A decade of CDK5. | Q34093501 | ||
| Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks | Q34183761 | ||
| Small molecule modulators of cyclin-dependent kinases for cancer therapy | Q34293568 | ||
| Negative regulators of cyclin-dependent kinases and their roles in cancers | Q34477825 | ||
| Cyclin E2, the cycle continues | Q34537668 | ||
| Analysis of ligand-macromolecule contacts: computational methods | Q34595208 | ||
| Protein kinases as targets for anticancer agents: from inhibitors to useful drugs | Q34792836 | ||
| Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. | Q34792851 | ||
| Issues and progress with protein kinase inhibitors for cancer treatment | Q35096214 | ||
| Cyclins that don't cycle--cyclin T/cyclin-dependent kinase-9 determines cardiac muscle cell size. | Q35107119 | ||
| Small molecules as inhibitors of cyclin-dependent kinases | Q35133499 | ||
| Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? | Q35594823 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | E204-21 | |
| P577 | publication date | 2006-03-24 | |
| P1433 | published in | The AAPS Journal | Q10695361 |
| P1476 | title | Selectivity and potency of cyclin-dependent kinase inhibitors | |
| P478 | volume | 8 |
| Q37336692 | ATP-noncompetitive inhibitors of CDK-cyclin complexes. |
| Q35728166 | Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo |
| Q34590906 | Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells. |
| Q28592308 | Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development |
| Q37640235 | Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases |
| Q34602967 | Cell cycle molecules define a pathway required for neuron death in development and disease |
| Q24656160 | Crystal structure of human CDK4 in complex with a D-type cyclin |
| Q38948559 | Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. |
| Q33742155 | Interactions between polymorphisms in the 3'untranslated region of the cyclin dependent kinase 6 gene and the human papillomavirus infection, and risk of cervical precancerous lesions |
| Q36922953 | MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. |
| Q52920061 | Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice. |
| Q55033883 | Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. |
| Q37151213 | Neurobiological applications of small molecule screening |
| Q39630367 | Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease |
| Q43891873 | Role of interactions and volume variation in discriminating active and inactive forms of cyclin-dependent kinase-2 inhibitor complexes |
| Q30501787 | Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4. |
| Q33829852 | Structural basis for the modulation of CDK-dependent/independent activity of cyclin D1. |
| Q33871868 | The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity |
| Q39239384 | miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. |
| Q33837378 | miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells |
| Q38701099 | miRNA-186 inhibits prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6. |
Search more.